Puerto Rico claims Brazil's #1 pharma export spot in 2026 YTD

Puerto Rico ranked ninth among destinations for Brazilian pharmaceutical exports at the close of 2025. Through the first four months of 2026, it reached #1, overtaking established destinations across the Americas and Europe. FOB tripled: from US$ 35.8 million to US$ 113.3 million in a single four-month window.

The fight for the top

The share swing defines the scale. Puerto Rico held 4.3% of Brazil's pharmaceutical export mix through 2025. Through April 2026, that share reached 12.4% — nearly three percentage points gathered from other destinations, implying either production capacity reallocation or the landing of a new supply contract.

Dosage-form pharmaceuticals — tablets, capsules, injectables, oral suspensions — are a category where supply contracts tend to run medium to long term, often tied to government tenders or hospital network procurement agreements. A threefold increase in four months is unusual in this segment and points to a specific event: a new contract win or a meaningful expansion of an existing one. Brazilian manufacturers have been building regulatory dossiers with US-adjacent agencies for years, and Anvisa-FDA alignment on GMP standards has shortened the approval runway considerably.

On the ground, what changes

Puerto Rico is the western hemisphere's most pharma-dense jurisdiction per capita, home to more than 50 plants operated by multinationals including Johnson & Johnson, AbbVie, and Pfizer. That it imports Brazilian pharmaceuticals signals that domestic manufacturers — EMS, Eurofarma, Hypera — have secured space in specific categories, competing on price or in off-patent molecules.

The logistics corridor works. Santos connects directly to San Juan, with average transit around 12–15 days — competitive versus European suppliers and within range for cold-chain requirements on injectables and biologics. Anvisa and Puerto Rico's FDA have mutual GMP recognition arrangements that smooth market entry for Brazilian pharma products.

What comes next

Brazil's pharmaceutical sector has been expanding its international footprint steadily, led by generics and branded similars. Puerto Rico is an unusual destination — it functions both as a final consumer market and as a redistribution platform for subsequent re-export to the continental US market.

If the #1 ranking holds through year-end, 2026 would mark the first time Puerto Rico has led the destination table for Brazilian pharmaceutical exports. The depreciated real continues to favor the exporter. Pharma is less exposed to international price volatility than agricultural or metal commodities, making the driver here primarily contractual: renewal or expansion of current agreements will determine whether volumes consolidate or drift back toward 2025 levels.

Watching whether other English- and Spanish-speaking Caribbean markets follow a similar pattern in coming MDIC releases could signal a broader hemispheric market push by Brazilian pharma manufacturers. Venezuela, Dominican Republic, and Jamaica have all been the subject of outreach by Brazilian generics producers in recent years — none yet at this volume, but the direction is consistent.

What this means for you

For exporters: Companies not yet operating in this corridor should map which molecules and dosage forms Puerto Rico absorbed in Q1 2026 — the specific product breakdown within this category reveals the highest-opportunity niches for new commercial proposals to Caribbean and US-adjacent markets.

For importers: Concentrated export growth to Puerto Rico in Q1 2026 can strain domestic inventory of certain pharmaceuticals, particularly high-volume generics. Build buffer inventory in Q2 if your procurement includes molecules that also appear in Brazil's recent export mix to the Caribbean.

Brazil has ridden pharmaceutical export cycles to the Caribbean before — the 2018 peak tied to Haiti and Cuba contracts ran for about 18 months before retreating. The difference this time is the counterpart: Puerto Rico is a buyer of a different scale.

Source: MDIC ComexStat